



## **Notice Concerning Grant Awarded to Consolidated Subsidiary (REPROCELL USA Inc.)**

May 22, 2026

### **1. Overview**

REPROCELL USA Inc. (Maryland, USA), a wholly owned subsidiary of the Company, has been selected to receive a grant (hereinafter, the "Grant") from the Maryland Stem Cell Research Fund (MSCRF), which is administered by the Maryland Technology Development Corporation (TEDCO), an affiliate of the State of Maryland government. We hereby announce the details as follows.

### **2. Overview of the Grant**

- **Project Name:** Generation of hypoimmune iPSC seed stocks for clinical applications
- **Grant Period:** June 2026 to May 2027
- **Maximum Grant Amount:** Total 398,535 USD (approximately 63 million JPY)

\*Calculated at 1 USD = 158 JPY

Upon receiving this Grant, REPROCELL USA Inc. will manufacture and commercialize clinical-grade universal donor iPS cells by combining clinical-grade iPS cells with gene-editing technology (StemEdit). This initiative is expected to contribute to reducing the risk of immune rejection in transplant medicine and will enable the strengthening of our product supply system to meet the needs of pharmaceutical and biotechnology companies. As a partner in the regenerative medicine field, our Group will continue to strive for further enhancement of our business foundation and business expansion.

The impact of this matter on our consolidated financial results is expected to be minor at this time; however, if any matters requiring disclosure arise in the future, we will promptly announce them.

**Universal donor iPS cells** These are iPS cells that have been modified using gene-editing technology to alter factors causing immune rejection (such as HLA), making them transplantable regardless of immunological compatibility. Because this eliminates the need to create individual cells for each patient, it enables mass production and advance stockpiling, which in turn leads to significant reductions in manufacturing costs and the establishment of a rapid supply system.

**About TEDCO-MSCRF** The Maryland Stem Cell Research Fund (MSCRF) is a grant program administered by TEDCO based on the initiatives of the State of Maryland, aiming to promote stem cell-related research and the commercialization of regenerative medicine within the state.

For details, please refer to the following link.: <https://www.msccrf.org/>